Rod Humerickhouse
Impact in
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
- Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Papers in
- Genetics 53
- Chronic Lymphocytic Leukemia Research 53
-
- Angiogenesis and VEGF in Cancer 12
- Co-authors
- Sari H. Enschede (32 shared papers)John F. Seymour (24 shared papers)Thomas J. Kipps (17 shared papers)William G. Wierda (25 shared papers)John F. Gerecitano (15 shared papers)Martin Dunbar (17 shared papers)Andrew W. Roberts (24 shared papers)Hao Xiong (15 shared papers)
- Journals
- Journal of Clinical Oncology (30 papers)Blood (29 papers)Clinical Cancer Research (5 papers)Cancer Research (5 papers)The Lancet Oncology (3 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
Rod Humerickhouse
107 papers receiving 8.2k citations
Rod Humerickhouse's Hit Papers
Peers
Comparison fields: 5 of 116
- Genetics 3.0k
- Hematology 2.2k
- Pathology and Forensic Medicine 1.9k
- Oncology 1.8k
- Immunology 1.1k
Countries citing papers authored by Rod Humerickhouse
This map shows the geographic impact of Rod Humerickhouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rod Humerickhouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rod Humerickhouse more than expected).
Fields of papers citing papers by Rod Humerickhouse
This network shows the impact of papers produced by Rod Humerickhouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rod Humerickhouse. The network helps show where Rod Humerickhouse may publish in the future.
Co-authors
The 25 scholars most cited alongside Rod Humerickhouse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 108 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia Hit paper breakdown → | 2015 | 1360 |
| 2 | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Hit paper breakdown → | 2010 | 674 |
| 3 | Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease Hit paper breakdown → | 2011 | 640 |
| 4 | Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia Hit paper breakdown → | 2018 | 609 |
| 5 | Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study Hit paper breakdown → | 2018 | 508 |
| 6 | Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors Hit paper breakdown → | 2011 | 470 |
| 7 | Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study Hit paper breakdown → | 2019 | 462 |
| 8 | Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. | 2000 | 301 |
| 9 | 2003 | 298 | |
| 10 | 2017 | 263 | |
| 11 | 2017 | 172 | |
| 12 | 2000 | 171 | |
| 13 | 2014 | 121 | |
| 14 | 2016 | 108 | |
| 15 | 2018 | 86 | |
| 16 | 2016 | 80 | |
| 17 | 2007 | 75 | |
| 18 | 2014 | 75 | |
| 19 | 2009 | 72 | |
| 20 | 2005 | 71 |
About Rod Humerickhouse
Rod Humerickhouse is a scholar working on Genetics, Molecular Biology, Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 108 papers that have together received 8.3k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (53 papers), Lymphoma Diagnosis and Treatment (20 papers), Advanced Breast Cancer Therapies (14 papers), Angiogenesis and VEGF in Cancer (12 papers), Cancer Treatment and Pharmacology (12 papers), Acute Lymphoblastic Leukemia research (11 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Multiple Myeloma Research and Treatments (8 papers). The work is most often cited by research in Genetics (3.0k citations), Hematology (2.2k citations), Pathology and Forensic Medicine (1.9k citations), Oncology (1.8k citations) and Immunology (1.1k citations). Rod Humerickhouse has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Sari H. Enschede, John F. Seymour, Thomas J. Kipps, William G. Wierda, John F. Gerecitano, Martin Dunbar, Andrew W. Roberts, Hao Xiong, Shekman Wong and Matthew S. Davids. Their work appears in journals such as Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.